Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2510924 + Durvalumab in Advanced Solid Tumors
NCT02737072Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Peptides, Small Molecules
01
Overview
Phase 1, open-label trial of LY2510924 in solid tumor (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants Who Experienced Dose-Limiting Toxicities and Maximum Tolerated Dose of LY2510924. Started Sep 2016; status: terminated.
02
Drugs
LY2510924
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02737072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737072.